Streetbeat News

Stock Prices

RNA

In the past three months, 7 analysts have provided ratings for Avidity Biosciences (NASDAQ:RNA), with a mix of bullish and somewhat bullish sentiments. The average 12-month price target has increased by 20.87% to $47.14. Analysts have raised their price targets, reflecting positive market sentiment and recent company performance.

Portfolio Pulse from Benzinga Insights

August 12, 2024 | 4:00 pm

AJG

Arthur J. Gallagher (NYSE:AJG) has significantly outperformed the market over the past decade, delivering an average annual return of 19.81%. A $100 investment in AJG 10 years ago would now be worth $609.05. The company's current market capitalization is $61.78 billion.

Portfolio Pulse from Benzinga Insights

August 12, 2024 | 4:00 pm

TRV

Travelers Companies (NYSE:TRV) has outperformed the market over the past 20 years with an average annual return of 9.47%, resulting in a $1000 investment growing to $6,194.30. The company currently has a market capitalization of $48.55 billion.

Portfolio Pulse from Benzinga Insights

August 12, 2024 | 4:00 pm

ATI

Analysts have provided mixed ratings for ATI (NYSE:ATI) over the past three months, with a majority being bullish. The average 12-month price target has increased to $74.0, reflecting an 8.82% rise from the previous target. Key analysts have raised their price targets, indicating positive sentiment towards ATI's future performance.

Portfolio Pulse from Benzinga Insights

August 12, 2024 | 4:00 pm

STRR

Star Equity has authorized a new stock repurchase program to buy back up to $1 million of its issued and outstanding common stock, as per an SEC filing on August 7.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 3:59 pm

LWLG

Lightwave Logic shares are trading lower following the company's Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 3:52 pm

ABBV

RVNC

Crown Laboratories, Inc. is set to acquire Revance Therapeutics, Inc. (NASDAQ:RVNC) for $6.66 per share in cash, valuing the deal at $924 million. This represents an 89% premium over Revance's closing price on August 9, 2024. Revance's lead product, Daxxify, competes with AbbVie's Botox and has shown strong sales growth. The transaction is expected to close by year-end, after which Revance will be delisted from Nasdaq.

Portfolio Pulse from Vandana Singh

August 12, 2024 | 3:50 pm

AZUL

Azul shares are trading lower after the company reported worse-than-expected Q2 sales results and a year-over-year decrease in adjusted EPADR results.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 3:50 pm

LEGN

Legend BioTech shares are trading higher after Scotiabank maintained a Sector Outperform rating and raised its price target from $70 to $76.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 3:49 pm

TMUS

Financial giants have made significant bullish moves on T-Mobile US (NASDAQ:TMUS) options, with 62% of traders showing bullish tendencies. Analysts have maintained positive ratings with price targets ranging from $197 to $220. The stock is currently priced at $194.09, with RSI indicators suggesting it may be approaching overbought territory.

Portfolio Pulse from Benzinga Insights

August 12, 2024 | 3:45 pm